Murphy & Mullick Capital Management Corp Acquires New Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Murphy & Mullick Capital Management Corp bought a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 265 shares of the financial services provider’s stock, valued at approximately $35,000.

Several other institutional investors also recently modified their holdings of IBB. TD Private Client Wealth LLC boosted its position in iShares Biotechnology ETF by 3.0% during the 4th quarter. TD Private Client Wealth LLC now owns 2,746 shares of the financial services provider’s stock worth $363,000 after buying an additional 81 shares during the period. Cullen Frost Bankers Inc. raised its stake in shares of iShares Biotechnology ETF by 1.5% during the fourth quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock valued at $748,000 after acquiring an additional 82 shares during the last quarter. Transcend Capital Advisors LLC lifted its holdings in shares of iShares Biotechnology ETF by 0.8% during the fourth quarter. Transcend Capital Advisors LLC now owns 10,958 shares of the financial services provider’s stock worth $1,449,000 after purchasing an additional 92 shares during the period. Chicago Partners Investment Group LLC lifted its holdings in shares of iShares Biotechnology ETF by 2.5% during the fourth quarter. Chicago Partners Investment Group LLC now owns 3,783 shares of the financial services provider’s stock worth $510,000 after purchasing an additional 94 shares during the period. Finally, WealthCare Investment Partners LLC grew its stake in shares of iShares Biotechnology ETF by 0.9% in the fourth quarter. WealthCare Investment Partners LLC now owns 10,348 shares of the financial services provider’s stock worth $1,375,000 after purchasing an additional 96 shares during the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Up 0.3 %

Shares of NASDAQ:IBB opened at $131.58 on Friday. The firm has a market cap of $6.22 billion, a P/E ratio of 27.83 and a beta of 0.84. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57. The business has a fifty day simple moving average of $136.21 and a 200 day simple moving average of $139.06.

iShares Biotechnology ETF Increases Dividend

The business also recently disclosed a dividend, which was paid on Friday, March 21st. Stockholders of record on Tuesday, March 18th were given a dividend of $0.1212 per share. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date was Tuesday, March 18th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.